Body composition in chemotherapy: The promising role of CT scans

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 16, Issue 5, 2013, Pages 525-533

  Prado, Carla M M ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

Author keywords

Body composition; chemotherapy; computerized tomography; muscle depletion; sarcopenia

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; PHENAZONE; SORAFENIB; SUNITINIB;

BILE DUCT CARCINOMA; BLOOD TOXICITY; BODY COMPOSITION; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CHEMORADIOTHERAPY; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; GLOMERULUS FILTRATION RATE; HEALTH STATUS; HEART OUTPUT; HUMAN; KIDNEY BLOOD FLOW; KIDNEY METASTASIS; LIVER BLOOD FLOW; LIVER CELL CARCINOMA; LIVER METASTASIS; MUSCLE ATROPHY; OBESITY; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; REVIEW;

EID: 84883310682     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e328363bcfb     Document Type: Review

References (26)

1. Laviano A, Molfino A, Rossi Fanelli F. Cancer-treatment toxicity: Can nutrition help? Nat Rev Clin Oncol 2012; 9:.
2. Cleeland CS, Allen JD, Roberts SA, et al. Reducing the toxicity of cancer therapy: Recognizing needs, taking action. Nat Rev Clin Oncol 2012; 9:471-478.
3. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 1994; 26:292-307.
4. Prado CM, Antoun S, Sawyer MB, Baracos VE. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr Opin Clin Nutr Metab Care 2011; 14:250-254.
5. Nawaratne S, Brien JE, Seeman E, et al. Relationships among liver and kidney volumes, lean body mass and drug clearance. Br J Clin Pharmacol 1998; 46:447-452.
6. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007; 13:3264-3268.
7. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15:2920-2926.
8. Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010; 21:1594-1598.
9. Prado CM, Lima IS, Baracos VE, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 2011; 67:93-101.
10. Awad S, Tan BH, Cui H, et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr 2012; 31:74-77.
11. Dalal S, Hui D, Bidaut L, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: A pilot study. J Pain Symptom Manage 2012; 44:181-191.
12. Del Fabbro E, Parsons H, Warneke CL, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist 2012; 17:1240-1245.
13. Mir O, Coriat R, Dhooge M, et al. Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2. Anticancer Drugs 2012; 23:739-744.
14. Mir O, Coriat R, Boudou-Rouquette P, et al. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pretreated with sorafenib. Med Oncol 2012; 29:2793-2799.
15. Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012; 7:e37563.
16. Parsons HA, Tsimberidou AM, Pontikos M, et al. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer 2012; 64:206-217.
17. Parsons HA, Baracos VE, Dhillon N, et al. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One 2012; 7:e29330.
18. Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 2013; 108:1034-1041.
19. Prado CM, Maia YL, Ormsbee MJ. Assessment of nutritional status in cancer -the relationship between body composition and pharmacokinetics. Anticancer Agents Med Chem 2013; 13. [Epub ahead of print]
20. Thibault R, Genton L, Pichard C. Body composition: Why, when and for who? Clin Nutr 2012; 31:435-447.
21. Jacquelin-Ravel N, Pichard C. Clinical nutrition, body composition and oncology: A critical literature review of the synergies. Crit Rev Oncol Hematol 2012; 84:37-46.
22. Tang PA, Heng DY, Choueiri TK. Impact of body composition on clinical outcomes in metastatic renal cell cancer. Oncologist 2011; 16:1484-1486.
23. Fearon K Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013; 10:90-99.
24. Dhooge M, Coriat R, Mir O, et al Feasibility of Gemcitabine Plus Oxaliplatin in Advanced Hepatocellular Carcinoma Patients with Child-Pugh B Cirrhosis. Oncology 2013; 84:32-38.
25. Alberta Health Services. A study comparing chemotherapy dosing based on either standard body surface area or lean body mass in patients with advanced lung cancer. Bethesda, Maryland: National Library of Medicine; 2012. [http://clinicaltrials.gov/ct2/show/NCT01624051 NLM Identifier: NCT01624051] (Accessed on 7 April 2013).
26. Pichard C, Baracos V, Attaix D. Would you buy a new tool to improve your practice? Curr Opin Clin Nutr Metab Care 2011; 14:221-222.